Is NCT07227311 recruiting in Torrance, CA?

Yes, NCT07227311 is currently recruiting participants at its Torrance, CA location. This multiple myeloma clinical trial is actively enrolling qualified participants.

How do I join the multiple myeloma clinical trial in Torrance?

To join this clinical trial in Torrance, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Torrance clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Multiple Myeloma Clinical Trial in Torrance, CA

About This Multiple Myeloma Study in Torrance

This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer medicines, can still treat the cancer effectively while causing fewer side effects, especially those affecting the eyes. The study will also look at how well the treatment works overall and how safe it is when administered to the participants.

Sponsor: GlaxoSmithKline

Who Can Participate

Inclusion Criteria

• Participants are eligible to be included in the study only if all of the following criteria apply: Applicable to All Arms - BPd, BVd, BKd:

Male or female, 18 years or older (at the time consent is obtained).

Have a confirmed diagnosis of Multiple Myeloma (MM) as defined by the International Myeloma Working Group (IMWG) criteria.

Eastern Cooperative Oncology Group (ECOG) performance status of zero to 2.

Have been previously treated with at least 1, but no more than 2, prior lines of MM therapy and must have documented disease progression during or after their most recent therapy.

Must have at least 1 aspect of measurable disease, defined as one the following:

Urine M-protein excretion ≥200 mg/24 h, or

Serum M-protein concentration ≥0.5 g/dL (≥5.0 g/L), or

Free Light Chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum free light chain ratio (\<0.26 or \>1.65) only if patient has no measurable urine or serum M spike.

Patients with a history of Autologous Stem Cell Transplant (ASCT) are eligible for study participation provided the following eligibility criteria are met:

ASCT was \>100 days prior to the first dose of study medication,

No active bacterial, viral, or fungal infection(s) present.

All prior treatment-related toxicities (defined by National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] v5.0) must be ≤Grade 1 at the time of enrollment, except for alopecia.

Adequate organ system functions as defined by the laboratory assessments.

Contraceptive requirements for men and women per local regulations; strict pregnancy prevention for women of childbearing potential (WOCBP), including negative pregnancy tests and use of highly effective contraception.

Male participants must refrain from sperm donation and must use a condom plus an additional highly effective method of contraception if sexually active with a woman of childbearing potential. Specific Inclusion Criteria for BPd arm: • Prior treatment must include a lenalidomide-containing regimen, with lenalidomide administered for at least 2 consecutive cycles.

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply: Applicable for all (BPd, BVd, BKd):

Active plasma cell leukemia at Screening.

Symptomatic amyloidosis, including active Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma proliferative disorder, and Skin changes (POEMS).

Previous or concurrent invasive malignancy other than MM, except:

The disease must be considered medically stable for at least 2 years; or

The patient must not be receiving active therapy, other than hormonal therapy for this disease.

Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.

Plasmapheresis within 7 days prior to the first dose of study intervention.

Patients after prior allogeneic stem cell transplant

Any major surgery within 4 weeks prior to start of treatment, except for bone stabilizing surgery.

Evidence of active mucosal or internal bleeding.

Intolerance or contraindications to anti-viral prophylaxis.

Current corneal epithelial disease except for mild punctate keratopathy.

Systemic anti-myeloma therapy (including chemotherapy and systemic steroids); prior treatment with an anti-MM monoclonal antibody drug within 30 days of receiving the first dose of study intervention.

Presence of active renal condition (infection, requirement for dialysis, or any other condition that could affect participant's safety). Patients with isolated proteinuria resulting from MM are eligible, provided they fulfill certain criteria

Received prior B-cell maturation antigen (BCMA)-targeted therapy.

Contact lenses are prohibited while receiving belantamab mafodotin treatment. Use may be restarted after a qualified eye care specialist confirms there are no other contraindications. Bandage contact lenses are permitted during study treatment as directed by the treating eye care specialist.

HIV infection unless well-controlled, no recent AIDS-defining infections, and adequate CD4+ count.

Significant liver dysfunction (ALT \>2.5x ULN, bilirubin \>1.5x ULN, cirrhosis, unstable liver/biliary disease).

Positive hepatitis B or C markers unless criteria for resolved infection are met.

Evidence of cardiovascular risk including any of the following: untreated arrhythmias, recent MI/ACS/angioplasty/bypass, NYHA III/IV heart failure, uncontrolled hypertension, QTc prolongation. Specific Exclusion Criteria for BPd Arm:

Received prior treatment with or intolerant to pomalidomide.

Active or history of venous and arterial thromboembolism within the past 3 months. Specific Exclusion Criteria for BVd Arm:

Intolerant to bortezomib or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m² twice weekly or within 60 days of completing that treatment).

Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain. Specific Exclusion Criteria for BKd Arm:

Intolerant to carfilzomib or refractory to carfilzomib (defined as progressive disease during treatment with a carfilzomib-containing regimen or within 60 days of completing that treatment).

Known history of allergy to captisol (i.e., cyclodextrin derivatives) used to solubilize carfilzomib.

Left ventricular ejection fraction \<40% as assessed by transthoracic echocardiogram.

Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrolment.

Intolerance to hydration due to pre-existing pulmonary or cardiac impairment.

Known pulmonary hypertension.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Torrance?

Yes, this clinical trial (NCT07227311) has an active research site in Torrance, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in Torrance, CA

If you're searching for multiple myeloma treatment options in Torrance, CA, this clinical trial (NCT07227311) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Torrance research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

Multiple Myeloma Clinical Trial in Torrance, CA

Expert Care in Torrance

IRB Approved

No-Cost Care

Apply for This Torrance Location

Why Participate?

Simple Process